Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: 360iResearch | PRODUCT CODE: 1602748

Cover Image

PUBLISHER: 360iResearch | PRODUCT CODE: 1602748

Animal Antibacterial Peptide Market by Peptide Type (Anionic Peptides, Cationic Peptides, Linear Cationic A-Helical Peptides), Product Origin (Cattle, Goat, Horse) - Global Forecast 2025-2030

PUBLISHED:
PAGES: 185 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF, Excel & 1 Year Online Access (Single User License)
USD 3939
PDF, Excel & 1 Year Online Access (Enterprise User License)
USD 6969

Add to Cart

The Animal Antibacterial Peptide Market was valued at USD 3.48 billion in 2023, expected to reach USD 4.06 billion in 2024, and is projected to grow at a CAGR of 16.92%, to USD 10.40 billion by 2030.

Animal Antibacterial Peptides (AAPs) are small protein molecules that form part of the innate immune response, showing broad-spectrum antibacterial activity, making them crucial in combating antibiotic-resistant bacterial strains. The necessity for AAPs stems from the escalating threat of antimicrobial resistance (AMR), which has prompted significant interest in developing alternative antimicrobial agents. These peptides are applied in various sectors, including medical, veterinary, agriculture, and food safety, where they serve as natural preservatives and disease-preventive agents. End-use scope spans pharmaceutical applications for treating bacterial infections, livestock health, crop protection, and food industry utilization to ensure safety and longevity.

KEY MARKET STATISTICS
Base Year [2023] USD 3.48 billion
Estimated Year [2024] USD 4.06 billion
Forecast Year [2030] USD 10.40 billion
CAGR (%) 16.92%

Market growth for AAPs is predominantly driven by the increasing demand for natural and sustainable antimicrobial solutions, paired with rising R&D investments. Key influencers include technological advancements in peptide synthesis and formulation, supportive regulatory policies, and heightened awareness of AMR challenges. Recent opportunities lie within biotechnological innovations to enhance peptide stability and efficacy and integration within the human microbiome space, where peptides could play critical roles in gut health as probiotic agents. To seize these opportunities, stakeholders should prioritize funding interdisciplinary research and forming strategic collaborations across sectors.

However, market expansion is impeded by high production costs, stability issues, and limited understanding of AAPs' long-term effects in vivo. Regulatory hurdles and competition from existing antibiotics and synthetic alternatives also pose significant challenges. Addressing these limitations necessitates innovation in cost-effective manufacturing processes, comprehensive studies on safety and applicability, and proactive regulatory engagement.

Research fronts that show promise include exploring genetic engineering to produce AAPs more efficiently, designing hybrid peptides with enhanced capabilities, and investigating non-traditional delivery systems such as nanoparticles for targeted action. The market for AAPs is intrinsically dynamic, warranting continuous exploration of synergies between traditional applications and emerging biotechnology sectors to foster business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Animal Antibacterial Peptide Market

The Animal Antibacterial Peptide Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing use of low levels of antibiotics as growth promoters in animal feeds
    • Extensive use of antibiotics to treat human or animal infections
    • Rising frequency of infectious diseases and the rising demand for effective and safe medicine
  • Market Restraints
    • Concerns in clinical applications such as the toxicity, and immunogenicity
  • Market Opportunities
    • Rapid rise in expenditure on animal healthcare and new product development efforts
    • Growing awareness to medications and therapies incorporating antimicrobial peptides
  • Market Challenges
    • Proliferating incidences of antibiotic resistance

Porter's Five Forces: A Strategic Tool for Navigating the Animal Antibacterial Peptide Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Animal Antibacterial Peptide Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Animal Antibacterial Peptide Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Animal Antibacterial Peptide Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Animal Antibacterial Peptide Market

A detailed market share analysis in the Animal Antibacterial Peptide Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Animal Antibacterial Peptide Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Animal Antibacterial Peptide Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Animal Antibacterial Peptide Market

A strategic analysis of the Animal Antibacterial Peptide Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Animal Antibacterial Peptide Market, highlighting leading vendors and their innovative profiles. These include Amicoat, Bayer AG, Boehringer Ingelheim GmbH, CPC Scientific Inc., Dechra Pharmaceuticals PLC, Eli Lilly and Company, Endovac Animal Health LLC, Fort Dodge Animal Health, JPT Peptide Technologies, Merck & Co. Inc., Mileutis LTD, Sanofi-Aventis Groupe S.A., Vetoquinol SA, Virbac S.A., and Zoetis Inc..

Market Segmentation & Coverage

This research report categorizes the Animal Antibacterial Peptide Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Peptide Type, market is studied across Anionic Peptides, Cationic Peptides, and Linear Cationic A-Helical Peptides.
  • Based on Product Origin, market is studied across Cattle, Goat, Horse, Pig, Poultry, and Sheep.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-4369010662C8

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing use of low levels of antibiotics as growth promoters in animal feeds
      • 5.1.1.2. Extensive use of antibiotics to treat human or animal infections
      • 5.1.1.3. Rising frequency of infectious diseases and the rising demand for effective and safe medicine
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns in clinical applications such as the toxicity, and immunogenicity
    • 5.1.3. Opportunities
      • 5.1.3.1. Rapid rise in expenditure on animal healthcare and new product development efforts
      • 5.1.3.2. Growing awareness to medications and therapies incorporating antimicrobial peptides
    • 5.1.4. Challenges
      • 5.1.4.1. Proliferating incidences of antibiotic resistance
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Animal Antibacterial Peptide Market, by Peptide Type

  • 6.1. Introduction
  • 6.2. Anionic Peptides
  • 6.3. Cationic Peptides
  • 6.4. Linear Cationic A-Helical Peptides

7. Animal Antibacterial Peptide Market, by Product Origin

  • 7.1. Introduction
  • 7.2. Cattle
  • 7.3. Goat
  • 7.4. Horse
  • 7.5. Pig
  • 7.6. Poultry
  • 7.7. Sheep

8. Americas Animal Antibacterial Peptide Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Animal Antibacterial Peptide Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Animal Antibacterial Peptide Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amicoat
  • 2. Bayer AG
  • 3. Boehringer Ingelheim GmbH
  • 4. CPC Scientific Inc.
  • 5. Dechra Pharmaceuticals PLC
  • 6. Eli Lilly and Company
  • 7. Endovac Animal Health LLC
  • 8. Fort Dodge Animal Health
  • 9. JPT Peptide Technologies
  • 10. Merck & Co. Inc.
  • 11. Mileutis LTD
  • 12. Sanofi-Aventis Groupe S.A.
  • 13. Vetoquinol SA
  • 14. Virbac S.A.
  • 15. Zoetis Inc.
Product Code: MRR-4369010662C8

LIST OF FIGURES

  • FIGURE 1. ANIMAL ANTIBACTERIAL PEPTIDE MARKET RESEARCH PROCESS
  • FIGURE 2. ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ANIMAL ANTIBACTERIAL PEPTIDE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. ANIMAL ANTIBACTERIAL PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ANIMAL ANTIBACTERIAL PEPTIDE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ANIMAL ANTIBACTERIAL PEPTIDE MARKET DYNAMICS
  • TABLE 7. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY ANIONIC PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY CATIONIC PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY LINEAR CATIONIC A-HELICAL PEPTIDES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY CATTLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY GOAT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY HORSE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PIG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY POULTRY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY SHEEP, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 20. AMERICAS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. ARGENTINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 34. ASIA-PACIFIC ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AUSTRALIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CHINA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. INDIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. INDONESIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. JAPAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. MALAYSIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. PHILIPPINES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. SINGAPORE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. SOUTH KOREA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. TAIWAN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. THAILAND ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. VIETNAM ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 61. EUROPE, MIDDLE EAST & AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 63. DENMARK ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. EGYPT ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. FINLAND ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. FRANCE ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. GERMANY ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. ISRAEL ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. ITALY ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. NETHERLANDS ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. NIGERIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. NORWAY ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. POLAND ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. QATAR ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. RUSSIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. SAUDI ARABIA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. SOUTH AFRICA ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. SPAIN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. SWEDEN ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SWITZERLAND ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. TURKEY ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED ARAB EMIRATES ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PEPTIDE TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED KINGDOM ANIMAL ANTIBACTERIAL PEPTIDE MARKET SIZE, BY PRODUCT ORIGIN, 2018-2030 (USD MILLION)
  • TABLE 104. ANIMAL ANTIBACTERIAL PEPTIDE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 105. ANIMAL ANTIBACTERIAL PEPTIDE MARKET, FPNV POSITIONING MATRIX, 2023
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!